EGFR and non-small cell lung carcinoma: In conclusion, more NSCLC patients with EGFR mutations can be identified by ARMS than by direct sequencing, and those identified by ARMS seems to be able to benefit more from tyrosine kinase inhibitors than do those identified by direct sequencing.